ASP-1929 not checked

Rakuten Medical, Inc. · PIT690 Laser System

FollowEvery change as it happens, and a Monday email
Stage
in Japan
Next date
Phase 3 trial completes
Trials
3 active
5 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)”In the company’s words, NCT06699212 on ClinicalTrials.gov
Tested for
Recurrent Head and Neck Squamous Cell Carcinoma (2 trials), Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Main trialPhase 3
“A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy”In the company’s words, NCT03769506 on ClinicalTrials.gov
Other names
cetuximab sarotalocan · PIT690 Laser System

Other drugs for Recurrent Head and Neck Squamous Cell Carcinoma

All 198 drugs for Recurrent Head and Neck Squamous Cell Carcinoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Dec 2025 ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Phase 3Recruiting Sep 2028 A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Phase 1/2Active, not recruiting Jun 2026 An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Phase 2Terminated 20 Nov 2023 ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases
Phase 2Unknown 11 Jul 2024 ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ASP-1929

Following is part of Solo: you see every change to ASP-1929 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in